MJardin Group, Inc.
MJardin Group, Inc.
Your view on MJARF
Overview
What the company does, where it operates, and who runs it.
About MJardin Group, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Ali Mahdavi
- Headquarters
- 1 Toronto Street, Toronto, ON, CA
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Ali Mahdavi
- Headquarters
- 1 Toronto Street, Toronto, ON, CA
MJardin Group, Inc., through its subsidiaries, cultivates, harvests, processes, and sells cannabis products in Canada and the United States.
The company also provides consulting services, including strategic capital and financing, project management services for cultivation, licensure support, facility design, systems implementation, facility and equipment leasing, construction oversight, facility ramp-up, and access to intellectual property held by the company to licensed cannabis operators with cultivation and retail businesses.
It owns, manages, or advises on a portfolio of 32 cannabis operations. The company was founded in 2014 and is headquartered in Ontario, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for MJardin Group, Inc., and the rating behind it. MJARF last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for MJardin Group, Inc.. Starting points for MJardin Group, Inc.: EPS -$0.39, beta 1.67 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for MJardin Group, Inc.. MJardin Group, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for MJardin Group, Inc.. Trailing twelve-month EPS for MJardin Group, Inc. stands at -$0.39. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for MJardin Group, Inc.. MJardin Group, Inc. has reported as a listed company since 2018. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
MJardin Group, Inc. valued side by side against its closest peers. MJardin Group, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold MJardin Group, Inc., and how their positions are changing. At a $90,140 market value, institutional positions materially move MJardin Group, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by MJardin Group, Inc. executives and directors. Shares of MJardin Group, Inc. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming MJardin Group, Inc.. MJardin Group, Inc. is a $90,140 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming MJardin Group, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for MJardin Group, Inc.. Coverage tracks MJardin Group, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.